Instrument Inactif

Autres langues Cyclacel Pharmaceuticals Inc Nasdaq

Actions

US23254L3069

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

30/04	Les plus fortes hausses de la mi-journée	MT
30/04	Les fonds négociés en bourse et les contrats à terme sur actions sont en baisse avant la réunion du FOMC.	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding	02/05
Top Midday Gainers	30/04
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting	30/04
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8.000001 million in funding	30/04
Cyclacel Pharmaceuticals Withdraws Securities Offering SEC Filing	29/04
Cyclacel Pharmaceuticals : April 2024 Corporate Presentation	02/04
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer	01/04
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	20/03
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000	19/03
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be presented at the American Association for Cancer Research Annual Meeting 2024	08/03
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit	07/03
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO and Investor Conference	21/02
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer	31/01
Cyclacel Pharmaceuticals, Inc. Announces Board Changes	30/01
Cyclacel Pharmaceuticals, Inc. Announces Executive Changes	30/01
Top Premarket Gainers	08/01
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024	03/01
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $0.026374 million in funding	22/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cyclacel Pharmaceuticals Inc Nasdaq

Actions

US23254L3069

Autres langues

Filtres